Please wait ...

Details for receptor: EP3

EndoNet ID: ENR00730

To link to the content of EndoNet use the EndoNet ID that is given on the detail pages in the format ENX0000, where X is a place holder for the type of the component (e. g. R for receptor or C for anatomical structure).
As URL for the linking append this ID to the detail page for this type of component.
For an hormone that would be:

It is also possible to use the search of EndoNet to link to the right detail page. The URL should look like
If the search pattern is unambigious the user is directed to the corresponding detail page.


  • EP3
  • prostanoid EP3 receptor
  • PGE receptor, EP3 subtype
  • PGE2-R
  • prostaglandin E2 receptor, EP3 subtype

General information

  • The EP(3) receptor was detected in foetal osteoclasts, osteoblasts and osteocytes, but only in osteoclasts and some osteoblasts from adult bone. [1]

Links to other resources

UniProt P43115
Ensembl ENST00000414819

Binding hormones

  • PGE2
    • Mature human osteoclasts present 2 subtypes of EP receptors, namely EP3 and EP4, that mediate different actions of PGE2 on these cells: activation of the EP4 receptors inhibits actin ring formation and activation of the EP3 receptors increases the number of lamellipodia. [2]
  • PGE1
  • PGE3
    • The results obtained demonstrate that, like PGE2, PGE3 interacts with EP3. [3]
    • Our demonstration that PGE3 interacts with EP3 suggests that antagonism of this receptor may promote the inhibitory effects of this prostaglandin as well. [3]

Anatomical structures with this receptor

  • uterus

  • kidney

  • small_intestine

  • placenta

  • osteoblast


    • positive interleukin 6
      • Il-6 is produced by osteoblasts, and its production is stimulated by PTH and PGE2. [4]
    • positive amphiregulin
      • In addition to PTH, PGE2 also strongly stimulates AR expression through the CREB phosphorylation pathway. [5]
  • osteoclast

  • monocyte

  • beta_cell_of_islet_of_Langerhans


    • negative insulin
      • EP3 is the Prostaglandin E2 receptor subtype whose post-receptor effect is to decrease adenylyl cyclase activity and, thereby, insulin secretion. [6]